Upstream Bio Announces Phase 3 Plans for Verekitug in Asthma and CRSwNP
Upstream Bio, Inc. has announced pivotal Phase 3 development plans for its TSLP antagonist verekitug in severe asthma and CRSwNP. The company aims to initiate both trials in Q1 2027 with a high-dose, quarterly administration regimen targeting broad patient populations.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day